"Valve performance starts the day of the procedure and matters for a lifetime. Explore the #SMARTtrial 1-year outcomes recently presented at #ACC2024. https://bit.ly/3TNCd7w Risk info: https://bit.ly/4cQKD6P"
About us
A global healthcare technology leader — boldly attacking the most challenging health problems facing humanity with innovations that transform lives.
- Website
-
http://medtronic.com
External link for Medtronic Cardiac and Vascular
- Industry
- Medical Device
- Company size
- 10,001+ employees
- Headquarters
- Minneapolis , MN
- Founded
- 1949
Updates
-
Cardiovascular disease is the leading cause of death for women worldwide,¹ yet women are still under-referred and undertreated for aortic valve replacement.²,³ Learn how the Medtronic #SMARTtrial is combatting underrepresentation in clinical research and making a difference for women with #AorticStenosis - https://bit.ly/4atf9SF #HealthEquity #TAVR Risk Info: https://bit.ly/43UG9b6 1. Vogel B, et al. Lancet. 2021 ;397 :2385-2438. 2. Erin Blakemore. Women are still underrepresented in clinical trials. Published June 27, 2022. Accessed on March 25, 2024. 3. L.A. McKeown. Stark inequities plague AVR rates for women, minorities in England. Published October 4, 2023. Accessed on March 25, 2023.
-
"Late-breaking clinical evidence presented at #ACC2024 shows fundamental design differences in #TAVR devices can impact valve performance. Explore the evidence. https://bit.ly/3U9gHv9 Risk info: https://bit.ly/4cOdzfp"
-
The #SMARTtrial 1-year outcomes uncover that Evolut™ #TAVR delivers superior valve performance vs. SAPIEN platform in women with small annuli.¹ Explore the evidence: https://bit.ly/3J8N9HF Risk Info: https://bit.ly/3Jbw1kK TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.
See How the SMART Trial Makes a Difference for Women
medtronic.com
-
The #SMARTtrial 1-year outcomes are here! Due to its focus on patients with small annuli, 87% of those enrolled in this late-breaking trial were women. Explore this revolutionary data and see how Evolut™ #TAVR makes a big difference for women with #AorticStenosis¹: https://bit.ly/43NEsw2 Risk Info: https://bit.ly/4aKWBwY TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.
See the Late-Breaking SMART Trial Data
medtronic.com
-
The Medtronic #SMARTtrial is our latest effort to address the underrepresentation of women in clinical research. As the largest randomized controlled trial to enroll 87% women, these new clinical insights will be pivotal in helping us evolve the future of #TAVR and make a difference for women with #AorticStenosis, together. Explore the evidence: https://bit.ly/4cQjBfB Risk Info: https://bit.ly/3xpA4qV
See How the SMART Trial Makes a Difference for Women
medtronic.com
-
The #SMARTtrial 1-year outcomes are here! Due to its focus on patients with small annuli, 87% of those enrolled in this late-breaking trial were women. Explore this revolutionary data and see how Evolut™ #TAVR makes a big difference for women with #AorticStenosis¹: https://bit.ly/3J9ttn3 Risk Info: https://bit.ly/3J9tszv TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.
See the Late-Breaking SMART Trial Data
medtronic.com
-
The #SMARTtrial 1-year outcomes show Evolut™️ #TAVR delivers superior valve performance vs. SAPIEN platform in small annulus patients with excellent early patient outcomes at 1 year. Explore the key takeaways. https://bit.ly/4an9vS0 Risk info: https://bit.ly/49qJRum
-
Medtronic Cardiac and Vascular reposted this
Join us for an insightful discussion around the current body of evidence in the TAVR space and how key trial data plays a role in valve selection.
Structural Heart Evidence Accountability
www.linkedin.com
-
Join us for an insightful discussion around the current body of evidence in the TAVR space and how key trial data plays a role in valve selection.
Structural Heart Evidence Accountability
www.linkedin.com